ARS Pharmaceuticals, Inc. SPRY Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- ARS Pharmaceuticals, Inc. (SPRY) reported comprehensive income (loss), net of tax, attributable to parent of -$60.84M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 78.5% year-over-year, from -$34.09M to -$60.84M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 71.0% compound annual growth rate (CAGR), from -$34.28M to -$171.39M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is a comprehensive measure of all changes in equity during a period, excluding transactions with owners, including net income and other comprehensive income items. It provides a broader view of financial performance than net income alone by incorporating unrealized gains or losses. Investors use this to evaluate the total change in the company's economic value over a reporting period.